Thioredoxin regulates cell cycle via the ERK1/2-cyclin d1 pathway

Antioxidants and Redox Signaling

Volumn 11, Issue 12, 2009, Pages 2957-2971

  Mochizuki, Michika ^a,b   Kwon, Yong Won ^a,c   Yodoi, Junji ^a   Masutani, Hiroshi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; ENDOTHELIAL CELL GROWTH FACTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; THIOREDOXIN;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL DEATH; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG CANCER; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; STRESS;

BASE SEQUENCE; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; CYCLIN D1; DNA PRIMERS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE KNOCKDOWN TECHNIQUES; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; THIOREDOXINS; TRANSCRIPTION FACTOR AP-1;

EID: 70449106252     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2009.2623     Document Type: Article

References (50)

1. Andoh T, Chock PB, and Chiueh CC. The roles of thio-redoxin in protection against oxidative stress-induced apo-ptosis in SH-SY5Y cells. J Biol Chem 277: 9655-9660, 2002.
2. Avval FZ and Holmgren A. Molecular mechanisms of thior-edoxin and glutaredoxin as hydrogen donors for mammalian S phase ribonucleotide reductase. J Biol Chem 284: 8233-8240, 2009.
3. Brown JR, Nigh E, Lee RJ, Ye H, Thompson MA, Saudou F, Pestell RG, and Greenberg ME. Fos family members induce cell cycle entry by activating cyclin D1. Mol Cell Biol 18: 5609-5619, 1998.
4. Chew EH, Lu J, Bradshaw TD, and Holmgren A. Thior-edoxin reductase inhibition by antitumor quinols: a quinol pharmacophore effect correlating to antiproliferative activity. FASEB J 22: 2072-2083, 2008.
5. Hartman H, Wu M, Buchanan BB, and Gerhart JC. Spinach thioredoxin m inhibits DNA synthesis in fertilized Xenopus eggs. Proc Natl Acad Sci U S A 90: 2271-2275, 1993.
6. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, and Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci U S A 94: 3633-3638, 1997.
7. Hirota K, Murata M, Itoh T, Yodoi J, and Fukuda K. Redox-sensitive transactivation of epidermal growth factor receptor by tumor necrosis factor confers the NF-kappa B activation. J Biol Chem 276: 25953-25958, 2001.
8. Holmgren A. Thioredoxin. Annu Rev Biochem 54: 237-271, 1985.
9. Hunter T and Pines J. Cyclins and cancer. II: cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994.
10. Ikeda M. Behaviour of sulfhydryl groups of sea urchin eggs under the blockage of cell division by UV and heat shock. Exp Cell Res 40: 282-291, 1965.
11. Jayaraman L, Murthy KG, Zhu C, Curran T, Xanthoudakis S, and Prives C. Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev 11: 558-570, 1997.
12. Kahlos K, Zhang J, Block ER, and Patel JM. Thioredoxin restores nitric oxide-induced inhibition of protein kinase C activity in lung endothelial cells. Mol Cell Biochem 254: 47-54, 2003.
13. Karin M, Liu Z, and Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 9: 240-246, 1997.
14. Kerkhoff E and Rapp UR. Cell cycle targets of Ras/Raf signalling. Oncogene 17: 1457-1462, 1998.
15. Koc A, Mathews CK, Wheeler LJ, Gross MK, and Merrill GF. Thioredoxin is required for deoxyribonucleotide pool maintenance during S phase. J Biol Chem 281: 15058-15063, 2006.
16. Kondoh K, Torii S, and Nishida E. Control of MAP kinase signaling to the nucleus. Chromosoma 114: 86-91, 2005.
17. Kontou M, Adelfalk C, Ramirez MH, Ruppitsch W, Hirsch-Kauffmann M, and Schweiger M. Overexpressed thio-redoxin compensates Fanconi anemia related chromosomal instability. Oncogene 21: 2406-2412, 2002.
18. Laurent TC, Moore EC, and Reichard P. Enzymatic synthesis of deoxyribonucleotides, IV: isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B. J Biol Chem 239: 3436-3444, 1964.
19. Lee SR, Yang KS, Kwon J, Lee C, Jeong W, and Rhee SG. Reversible inactivation of the tumor suppressor PTEN by H2O2. J Biol Chem 277: 20336-20342, 2002.
20. Lenormand P, Sardet C, Pages G, L'Allemain G, Brunet A, and Pouyssegur J. Growth factors induce nuclear translo-cation of MAP kinases (p42mapk and p44mapk) but not of their activator MAP kinase kinase (p45mapkk) in fibroblasts. J Cell Biol 122: 1079-1088, 1993.
21. Matsui M, Oshima M, Oshima H, Takaku K, Maruyama T, Yodoi J, and Taketo MM. Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. Dev Biol 178: 179-185, 1996.
22. Matsumura I, Mizuki M, and Kanakura Y. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies. Cancer Sci 99: 479-485, 2008.
23. Meuillet EJ, Mahadevan D, Berggren M, Coon A, and Powis G. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. Arch Biochem Biophys 429: 123-133, 2004.
24. Mitsui A, Hamuro J, Nakamura H, Kondo N, Hirabayashi Y, Ishizaki-Koizumi S, Hirakawa T, Inoue T, and Yodoi J. Overexpression of human thioredoxin in transgenic mice controls oxidative stress and life span. Antioxid Redox Signal 4: 693-696, 2002.
25. Motokura T and Arnold A. Cyclin D and oncogenesis. Curr Opin Genet Dev 3: 5-10, 1993.
26. Muller EG. A glutathione reductase mutant of yeast accumulates high levels of oxidized glutathione and requires thioredoxin for growth. Mol Biol Cell 7: 1805-1813, 1996.
27. Muller EG. Thioredoxin deficiency in yeast prolongs S phase and shortens the G1 interval of the cell cycle. J Biol Chem 266: 9194-9202, 1991.
28. Natsuyama S, Noda Y, Narimoto K, Umaoka Y, and Mori T. Release of two-cell block by reduction of protein disulfide with thioredoxin from Escherichia coli in mice. J Reprod Fertil 95: 649-656, 1992.
29. Nishida E and Gotoh Y. The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem Sci 18: 128-131, 1993.
30. Nishiyama A, Matsui M, Iwata S, Hirota K, Masutani H, Nakamura H, Takagi Y, Sono H, Gon Y, and Yodoi J. Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 274: 21645-21650, 1999.
31. Noguchi T, Takeda K, Matsuzawa A, Saegusa K, Nakano H, Gohda J, Inoue J, and Ichijo H. Recruitment of tumor necrosis factor receptor-associated factor family proteins to apoptosis signal-regulating kinase 1 signalosome is essential for oxidative stress-induced cell death. J Biol Chem 280: 37033-37040, 2005.
32. Rhee SG, Chae HZ, and Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med 38: 1543-1552, 2005.
33. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, and Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17: 2596-2606, 1998.
34. Sasada T, Iwata S, Sato N, Kitaoka Y, Hirota K, Nakamura K, Nishiyama A, Taniguchi Y, Takabayashi A, and Yodoi J. Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity. J Clin Invest 97: 2268-2276, 1996.
35. Shaulian E and Karin M. AP-1 in cell proliferation and survival. Oncogene 20: 2390-2400, 2001.
36. Shen Q, Uray IP, Li Y, Krisko TI, Strecker TE, Kim HT, and Brown PH. The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene 27: 366-377, 2008.
37. Sherr CJ. G1 phase progression: cycling on cue. Cell 79: 551-555, 1994.
38. Tagaya Y, Maeda Y, Mitsui A, Kondo N, Matsui H, Hamuro J, Brown N, Arai K, Yokota T, Wakasugi H, and Yodoi J. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin: possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J 8: 757-764, 1989.
39. Tagaya Y, Wakasugi H, Masutani H, Nakamura H, Iwata S, Mitsui A, Fujii S, Wakasugi N, Tursz T, and Yodoi J. Role of ATL-derived factor (ADF) in the normal and abnormal cellular activation: involvement of dithiol related reduction. Mol Immunol 27: 1279-1289, 1990.
40. Tetsu O and McCormick F. Beta-catenin regulates expression of cyclinD1in colon carcinoma cells. Nature 398: 422-426, 1999.
41. Torii S, Yamamoto T, Tsuchiya Y, and Nishida E. ERK MAP kinase in G cell cycle progression and cancer. Cancer Sci 97: 697-702, 2006.
42. Treisman R. Ternary complex factors: growth factor regulated transcriptional activators. Curr Opin Genet Dev 4: 96-101, 1994.
43. Ueda-Taniguchi Y, Furuke K, Masutani H, Nakamura H, and Yodoi J. Cell cycle inhibition of HTLV-I transformed T cell lines by retinoic acid: the possible therapeutic use of thioredoxin reductase inhibitors. Oncol Res 7: 183-189, 1995.
44. Ueno M, Masutani H, Arai RJ, Yamauchi A, Hirota K, Sakai T, Inamoto T, Yamaoka Y, Yodoi J, and Nikaido T. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 274: 35809-35815, 1999.
45. Wakasugi N, Tagaya Y, Wakasugi H, Mitsui A, Maeda M, Yodoi J, and Tursz T. Adult T-cell leukemia-derived factor/ thioredoxin, produced by both human T-lymphotropic virus type I-and Epstein-Barr virus-transformed lymphocytes, acts asanautocrinegrowthfactor andsynergizeswithinterleukin 1 and interleukin 2. Proc Natl Acad Sci U S A 87: 8282-8286, 1990.
46. Watanabe G, Howe A, Lee RJ, Albanese C, Shu IW, Karnezis AN, Zon L, Kyriakis J, Rundell K, and Pestell RG. Induction of cyclin D1 by simian virus 40 small tumor antigen. Proc Natl Acad Sci U S A 93: 12861-12866, 1996.
47. Witte S, Villalba M, Bi K, Liu Y, Isakov N, and Altman A. Inhibition of the c-Jun N-terminal kinase/AP-1 and NF-kappaB pathways by PICOT, a novel protein kinase C-interacting protein with a thioredoxin homology domain. J Biol Chem 275: 1902-1909, 2000.
48. Xanthoudakis S and Curran T. Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity. EMBO J 11: 653-665, 1992.
49. Yan YX, Nakagawa H, Lee MH, and Rustgi AK. Transforming growth factor-alpha enhances cyclin D1 transcription through the binding of early growth response protein to a cis-regulatory element in the cyclin D1 promoter. J Biol Chem 272: 33181-33190, 1997.
50. Yokomizo A, Ono M, Nanri H, Makino Y, Ohga T, Wada M, Okamoto T, Yodoi J, Kuwano M, and Kohno K. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res 55: 4293-4296, 1995